Samsung Bioepis parent slumps after claim of accounting malpractice

3 May 2018

Shares in contract manufacturing organization Samsung BioLogics (KRX: 207940) slumped almost a fifth this week after financial regulators said the biopharmaceutical firm was in violation of accounting rules.

Samsung BioLogics is the parent of biosimilars specialist Samsung Bioepis and itself a subsidiary in the sprawling South Korean Samsung empire. US biotech Biogen (Nasdaq: BIIB) has a small stake in the biosimilars business, with an option to extend this.

The probe was initiated after questions were raised regarding a dramatic turnaround in the firm’s fortunes. Samsung BioLogics had reported losses for four years in a row, but in 2015 said it made a net profit of 1.9 trillion Korean won, equivalent to 1.8 billion US dollars.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK